REGULATORY

Generic Industry Asks for Govt Support for Continuous Manufacturing to Boost Int’l Competitiveness: Public-Private Confab

April 17, 2018

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Japanese generic industry on April 16 called for the government’s support for the commercialization of innovative production technologies such as continuous manufacturing that could help it retrench costs and beef up international competitiveness. Speaking at the first public-private dialogue…

To read the full story

Pharma Leaders Air Grievances on Pricing Reform Package at New MHLW Confab
April 17, 2018

REGULATORY

Panel Clears Zolgensma Intrathecal Form to Expand Use in Older SMA Patients
March 10, 2026
Japan Approves MSD’s HIV Combo Idvynso
March 9, 2026
MHLW Updates Elective Care LLP List; Target Products Down Sharply to 776
March 9, 2026
MHLW Orders Label Revisions for Cancer Drugs, Anticoagulant over Bleeding Risk
March 9, 2026
Japan Health Minister Lauds Approval of iPSC-Based Therapies
March 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…